| 1.745 -0.07 (-3.86%) | 10-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.93  |
1-year : | 3.52 |
| Resists | First : | 2.51 |
Second : | 3.01 |
| Pivot price | 2.09 |
|||
| Supports | First : | 1.71 |
Second : | 1.42 |
| MAs | MA(5) : | 1.96 |
MA(20) : | 2.2 |
| MA(100) : | 2.47 |
MA(250) : | 2.39 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 2.7 |
D(3) : | 7.5 |
| RSI | RSI(14): 26.9 |
|||
| 52-week | High : | 3.59 | Low : | 1.5 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ABOS ] has closed below the lower bollinger band by 8.3%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 13.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.86 - 1.87 | 1.87 - 1.88 |
| Low: | 1.68 - 1.7 | 1.7 - 1.71 |
| Close: | 1.72 - 1.75 | 1.75 - 1.77 |
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.
Fri, 09 Oct 2026
ABOS: Acumen Pharmaceuticals Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Wed, 16 Sep 2026
Acumen Pharmaceuticals to Webcast Investor Day; ALTITUDE-AD topline expected late 2026, EBD IND targeted mid-2027 - TradingView
Thu, 10 Sep 2026
Acumen will meet investors online Sept. 16 - Stock Titan
Wed, 02 Sep 2026
An Alzheimer’s drug developer will join two live online events Sept. 9 and 10 - Stock Titan
Thu, 13 Aug 2026
Citi Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Wed, 12 Aug 2026
Acumen Pharmaceuticals Inc (ABOS) (Q2 2026) Earnings Call Highlights: Advancing Sabirnetug ... - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 72 (M) |
| Shares Float | 37 (M) |
| Held by Insiders | 6.7 (%) |
| Held by Institutions | 66.5 (%) |
| Shares Short | 3,080 (K) |
| Shares Short P.Month | 3,160 (K) |
| EPS | -1.68 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.79 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -45.8 % |
| Return on Equity (ttm) | -120.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -1.21 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.46 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -92 (M) |
| Levered Free Cash Flow | -57 (M) |
| PE Ratio | -1.04 |
| PEG Ratio | 0 |
| Price to Book value | 2.2 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.38 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|